BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, the combination of a TKI with ABT-737 represents a potential therapeutic strategy to overcome TKI resistance in CML cell lines, especially those that harbored the BIM deletion polymorphism.